CN101443036A - 癌症治疗和预防的试剂和方法 - Google Patents

癌症治疗和预防的试剂和方法 Download PDF

Info

Publication number
CN101443036A
CN101443036A CNA2007800162837A CN200780016283A CN101443036A CN 101443036 A CN101443036 A CN 101443036A CN A2007800162837 A CNA2007800162837 A CN A2007800162837A CN 200780016283 A CN200780016283 A CN 200780016283A CN 101443036 A CN101443036 A CN 101443036A
Authority
CN
China
Prior art keywords
cell
thapsigargin
cells
tumor
described method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800162837A
Other languages
English (en)
Chinese (zh)
Inventor
K·R·尼亚齐
S·拉比扎德赫
D·E·布雷德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buck Institute for Research on Aging
Original Assignee
Buck Institute for Research on Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Institute for Research on Aging filed Critical Buck Institute for Research on Aging
Publication of CN101443036A publication Critical patent/CN101443036A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2007800162837A 2006-03-27 2007-03-27 癌症治疗和预防的试剂和方法 Pending CN101443036A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/389,695 US9107863B2 (en) 2006-03-27 2006-03-27 Reagents and methods for cancer treatment and prevention
US11/389,695 2006-03-27

Publications (1)

Publication Number Publication Date
CN101443036A true CN101443036A (zh) 2009-05-27

Family

ID=38533710

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800162837A Pending CN101443036A (zh) 2006-03-27 2007-03-27 癌症治疗和预防的试剂和方法

Country Status (8)

Country Link
US (4) US9107863B2 (enExample)
EP (2) EP2974738B1 (enExample)
JP (2) JP5422377B2 (enExample)
CN (1) CN101443036A (enExample)
AU (1) AU2007245169B2 (enExample)
CA (1) CA2647542A1 (enExample)
ES (2) ES2548435T3 (enExample)
WO (1) WO2007126787A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112891354A (zh) * 2021-03-18 2021-06-04 新乡医学院 MDM2抑制剂Nutlin-3a在制备激活内质网应激诱导的癌细胞凋亡药物中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376495B2 (ja) 1992-08-18 2003-02-10 ソニー株式会社 接着剤の塗布方法及び接着治具
US9107863B2 (en) * 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention
CZ300806B6 (cs) * 2007-07-18 2009-08-12 Ústav experimentální mediciny AV CR, v.v.i. Imunostimulacní úcinky trilobolidu a zpusob jeho prípravy
BR112015023088A2 (pt) * 2013-03-15 2017-11-21 Genspera Inc método para preparar um composto, e, composto
EP2796137A1 (en) * 2013-04-22 2014-10-29 Universität des Saarlandes SERCA inhibitor and Calmodulin antagonist combination

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
IN165717B (enExample) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
JP2001010973A (ja) * 1999-06-29 2001-01-16 Dnavec Research Inc がんワクチン
PL354997A1 (en) * 1999-09-25 2004-03-22 University Of Iowa Research Foundation Immunostimulatory nucleic acids
US7056491B2 (en) * 2000-11-08 2006-06-06 Wisconsin Alumni Research Foundation Monoterpenes and sesquiterpenes as chemotherapeutic and radiation sensitizers and immunomodulators
CA2356438A1 (en) * 2001-09-05 2003-03-05 Andre Pichette Use of terpenes and derivatives as potentiators of antitumor agents in the treatment of cancers
EP2128267A2 (en) * 2001-10-31 2009-12-02 Astellas Pharma Inc. Methods of evaluating phosphatase inhibitors
US20030235818A1 (en) * 2002-04-08 2003-12-25 Vsevolod Katritch Immunogenic peptides, and method of identifying same
AU2003301526A1 (en) 2002-10-25 2004-05-13 University Of Connecticut Health Center Immunotherapy of cancer through controlled cell lysis
ES2469670T3 (es) * 2003-11-30 2014-06-18 Yeda Research And Development Co., Ltd. Métodos y agentes para inmunomodulaci�n y métodos para identificar inmunomoduladores
US9107863B2 (en) * 2006-03-27 2015-08-18 The Buck Institute For Age Reasearch Reagents and methods for cancer treatment and prevention

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112891354A (zh) * 2021-03-18 2021-06-04 新乡医学院 MDM2抑制剂Nutlin-3a在制备激活内质网应激诱导的癌细胞凋亡药物中的应用

Also Published As

Publication number Publication date
EP2004219A2 (en) 2008-12-24
AU2007245169A1 (en) 2007-11-08
ES2655909T3 (es) 2018-02-22
WO2007126787A3 (en) 2008-10-23
US9885704B2 (en) 2018-02-06
JP2014028815A (ja) 2014-02-13
US8895031B2 (en) 2014-11-25
US20100278874A1 (en) 2010-11-04
JP2009535298A (ja) 2009-10-01
US9107863B2 (en) 2015-08-18
CA2647542A1 (en) 2007-11-08
JP5422377B2 (ja) 2014-02-19
US20160069864A1 (en) 2016-03-10
EP2004219A4 (en) 2010-06-30
EP2974738B1 (en) 2017-11-15
AU2007245169B2 (en) 2012-05-24
US20180128816A1 (en) 2018-05-10
JP5712257B2 (ja) 2015-05-07
WO2007126787A2 (en) 2007-11-08
US20070224207A1 (en) 2007-09-27
ES2548435T3 (es) 2015-10-16
EP2004219B1 (en) 2015-09-16
EP2974738A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
US20180128816A1 (en) Reagents and Methods for Cancer Treatment and Prevention
JP5662309B2 (ja) 腫瘍性疾患を治療するための組成物および方法
Brusa et al. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity
Jérôme et al. Cytotoxic T lymphocytes responding to low dose TRP2 antigen are induced against B16 melanoma by liposome-encapsulated TRP2 peptide and CpG DNA adjuvant
EP4021487B1 (en) Antigenic peptides for prevention and treatment of b-cell malignancy
US20240335511A1 (en) Therapeutic rna for treating cancer
WO2020225779A1 (en) Rig-i agonists for cancer treatment and immunotherapy
JP2023538077A (ja) がんの治療方法
WO2002074939A1 (fr) Utilisation d'une fraction membranaire de bacteries a gram negatif pour induire la maturation des cellules dendritiques
US20240041999A1 (en) Therapeutic RNA for Treating Cancer
US20230233474A1 (en) Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
AU2024278682A1 (en) Cancer antigens
Tseng et al. Induction of immune responses and phosphatidylserine exposure by TLR9 activation results in a cooperative antitumor effect with a phosphatidylserine-targeting prodrug
Bot et al. Cancer vaccines
KR102352715B1 (ko) Il-21을 이용한 항원 특이적 cd8+ t 세포의 증식 촉진 또는 대량 배양 방법
JP2003512335A (ja) メラノーマワクチン並びにその製造方法及び使用方法
US20240390462A1 (en) Treatment Schedule for Cytokine Proteins
CN116761625A (zh) 癌症免疫治疗
Yamaoka et al. WS/PP-024b-11 Spatiotemporal regulation of heat shock protein 90-chaperoned self-DNA and CpG-oligodeoxynucleotide for type-I interferon induction via targeting to static early endosome Y. Tamura, K. Saito, K. Okuya, T. Torigoe, N. Sato. Sapporo Medical University School of Medicine, Sapporo, Japan

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090527